The content on this site is intended for healthcare professionals only
Dr Timothy Yap speaks to ecancer as part of the AACR 2022 meeting about a study evaluating the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumours with DNA damage response defects.
He reports that clinical benefit with disease control for at least 16 weeks was achieved in at least 35% of patients treated with elimusertib and that durable responses were seen over a variety of cancer types.
Dr Yap also explains that the adverse events seen during treatment were reversible and manageable with dose interruption, reduction and supportive measures.
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
